Vesalius Biocapital leads €2.7m financing round for Trinean
Vesalius Biocapital, Capital-E, Baekeland II Fund and Fidimec have invested €2.7m in Belgian biotechnology business Trinean.
All investors had previously invested in the company. The new capital will be used to support the company's commercial growth and the expansion of its product range.
Company
Trinean is a biotechnology and instrumentation company based in Ghent, Belgium. The business is specialised in micro-volume molecular spectroscopy. Its prime product, the DropSense96, a high capacity spectrophotometer, was launched in 2009.
The company's analytical platform includes spectrophotometry instruments, software, standardised sample analysis and lab-automation tools.
Trinean was founded by Bert Luyssaert, Kris Naessens and Ronny Bockstaele in 2006. The company was previously affiliated with the University of Ghent.
People
Philippe Stats is CEO of Trinean.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








